Ellen Viveka Iacobaeus

Publications
CV
Public outreach and news

Articles

Article: NEUROLOGY. 2024;102(6):e208051
Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis A Swedish Nationwide Study
Mouresan EF; Mentesidou E; Berglund A; Mckay KA; Hillert J; Iacobaeus E
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2024;95(2):125-133
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
Silfverberg T; Zjukovskaja C; Ljungman P; Nahimi A; Ahlstrand E; Dreimane A; Einarsdottir S; Fagius J; Iacobaeus E; Hagglund H; Lange N; Lenhoff S; Lycke J; Mellergard J; Piehl F; Svenningsson A; Tolf A; Cherif H; Carlson K; Burman J
Article: JOURNAL OF CLINICAL MEDICINE. 2024;13(2):355
Relapses and Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab: A Swedish Single-Center Study
Carlsson O; Jonsson DI; Brundin L; Iacobaeus E
Article: LEUKEMIA. 2023;37(4):888-900
Cognitive impairments correlate with increased central nervous system immune activation after allogeneic haematopoietic stem cell transplantation
Boberg E; Kadri N; Hagey DWW; Schwieler L; El Andaloussi S; Erhardt S; Iacobaeus E; Le Blanc K
Article: PLOS ONE. 2023;18(1):e0280376
Inventory study of an early pandemic COVID-19 cohort in South-Eastern Sweden, focusing on neurological manifestations
Ahmadpour D; Kristoffersson A; Fredrikson M; Huang-Link Y; Eriksson A; Iacobaeus E; Landtblom A-M; Haghighi S
Article: VACCINES. 2022;10(12):2046
Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report
Kits A; Pantalone MR; Illies C; Antovic A; Landtblom A-M; Iacobaeus E
Article: BONE MARROW TRANSPLANTATION. 2022;57(3):360-369
Reduced prefrontal cortex and sympathetic nervous system activity correlate with fatigue after aHSCT
Boberg E; Iacobaeus E; Greenfield MS; Wang Y; Msghina M; Le Blanc K
Article: LAKARTIDNINGEN. 2020;117:20129
Multipel skleros och covid-19 – kunskapen ännu begränsad.
Iacobaeus E; Burman J; Landtblom A-M
Article: JOURNAL OF CLINICAL MEDICINE. 2019;8(12):E2102-2102
Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis-A Phase I Study
Iacobaeus E; Kadri N; Lefsihane K; Boberg E; Gavin C; Andren AT; Lilja A; Brundin L; Le Blanc K
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2249
The Complement System Is Essential for the Phagocytosis of Mesenchymal Stromal Cells by Monocytes
Gavin C; Meinke S; Heldring N; Heck KA; Achour A; Iacobaeus E; Le Blanc K; Kadri N; Hoglund P
Article: IMMUNOLOGY AND CELL BIOLOGY. 2018;96(8):820-830
Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis
Iacobaeus E; Douagi I; Jitschin R; Marcusson-Stahl M; Andren AT; Gavin C; Lefsihane K; Davies LC; Mougiakakos D; Kadri N; Le Blanc K
Article: NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2018;44(4):404-416
Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro
Bridel C; Koel-Simmelink MJA; Peferoen L; Troletti CD; Durieux S; Gorter R; Nutma E; Gami P; Iacobaeus E; Brundin L; Kuhle J; Vrenken H; Killestein J; Piersma SR; Pham TV; De Vries HE; Amor S; Jimenez CR; Teunissen CE
Article: NEUROLOGY. 2018;90(6):e498-e506
The national incidence of PML in Sweden, 1988-2013
Iacobaeus E; Burkill S; Bahmanyar S; Hakim R; Bystrom C; Fored M; Olsson T; Brundin L; Montgomery S
Article: STEM CELLS TRANSLATIONAL MEDICINE. 2017;6(10):1840-1851
Dynamic Changes in Brain Mesenchymal Perivascular Cells Associate with Multiple Sclerosis Disease Duration, Active Inflammation, and Demyelination
Iacobaeus E; Sugars RV; Andren AT; Alm JJ; Qian H; Frantzen J; Newcombe J; Alkass K; Druid H; Bottai M; Roytta M; Le Blanc K
Article: ALZHEIMER'S AND DEMENTIA: DIAGNOSIS, ASSESSMENT AND DISEASE MONITORING. 2017;8:111-126
Consensus guidelines for lumbar puncture in patients with neurological diseases.
Engelborghs S; Niemantsverdriet E; Struyfs H; Blennow K; Brouns R; Comabella M; Dujmovic I; van der Flier W; Frölich L; Galimberti D; Gnanapavan S; Hemmer B; Hoff E; Hort J; Iacobaeus E; Ingelsson M; Jan de Jong F; Jonsson M; Khalil M; Kuhle J; Lleó A; de Mendonça A; Molinuevo JL; Nagels G; Paquet C; Parnetti L; Roks G; Rosa-Neto P; Scheltens P; Skårsgard C; Stomrud E; Tumani H; Visser PJ; Wallin A; Winblad B; Zetterberg H; Duits F; Teunissen CE
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2014;85(10):1116-1121
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
Burman J; Iacobaeus E; Svenningsson A; Lycke J; Gunnarsson M; Nilsson P; Vrethem M; Fredrikson S; Martin C; Sandstedt A; Uggla B; Lenhoff S; Johansson J-E; Isaksson C; Hagglund H; Carlson K; Fagius J
Article: MULTIPLE SCLEROSIS JOURNAL. 2013;19(13):1802-1809
Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis
Teunissen C; Menge T; Altintas A; Alvarez-Cermeno JC; Bertolotto A; Berven FS; Brundin L; Comabella M; Degn M; Deisenhammer F; Fazekas F; Franciotta D; Frederiksen JL; Galimberti D; Gnanapavan S; Hegen H; Hemmer B; Hintzen R; Hughes S; Iacobaeus E; Kroksveen AC; Kuhle J; Richert J; Tumani H; Villar LM; Drulovic J; Dujmovic I; Khalil M; Bartos A
Article: LUPUS. 2013;22(3):307-311
Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents
Iacobaeus E; Hopia L; Khademi M; Lunden M; Hammarin A-L; Svenungsson E; Andersson M
Article: PLOS ONE. 2011;6(5):e19138
The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis
Iacobaeus E; Amoudruz P; Strom M; Khademi M; Brundin L; Hillert J; Kockum I; Malmstrom V; Olsson T; Tham E; Piehl F
Article: MULTIPLE SCLEROSIS JOURNAL. 2011;17(3):335-343
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2009;80(10):1110-1115
Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis
Vogt MHJ; Teunissen CE; Iacobaeus E; Heijnen DAM; Breij ECW; Olsson T; Brundin L; Killestein J; Dijkstra CD
Article: NEUROLOGY. 2009;72(15):1322-1329
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJA; Schepens M; Bouwman F; Twaalfhoven HAM; Blom HJ; Jakobs C; Dijkstra CD
Article: MULTIPLE SCLEROSIS JOURNAL. 2009;15(1):28-35
Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA
Iacobaeus E; Ryschkewitsch C; Gravell M; Khademi M; Wallstrom E; Olsson T; Brundin L; Major EO
Article: NATURE GENETICS. 2007;39(9):1108-1113
Variation in interleukin 7 receptor a chain (IL7R) influences risk of multiple sclerosis
Lundmark F; Duvefelt K; Iacobaeus E; Kockum I; Wallstroem E; Khademi M; Oturai A; Ryder LP; Saarela J; Harbo HF; Celius EG; Salter H; Olsson T; Hillert J
Article: GENETICS. 2005;170(1):283-289
Eae19, a new locus on rat chromosome 15 regulating experimental autoimmune encephalomyelitis
Sheng JR; Jagodic M; Dahlman I; Becanovic K; Nohra R; Marta M; Iacobaeus E; Olsson T; Wallström E
Article: JOURNAL OF NEUROIMMUNOLOGY. 2001;116(2):168-177
Curative effects of recombinant human interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis
Di Marco R; Khademi M; Wallstrom E; Iacobaeus E; Salvaggio A; Caracappa S; Papoian R; Nicoletti F; Olsson T
Show more

All other publications

Review: EUROPEAN JOURNAL OF NEUROLOGY. 2024;31(7):e16284
Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: A systematic review and meta-analysis
Hagbohm C; Ouellette R; Flanagan EP; Jonsson DI; Piehl F; Banwell B; Wickstroem R; Iacobaeus E; Granberg T; Ineichen BV
Preprint: BIORXIV. 2024
ATF4 orchestrates IL-1α-induced senescence in adult neural stem cells
Neumann S; Thelin EP; Sankavaram SR; Persson S; Fonseca L; Moruzzi N; Iacobaeus E; Bergsland M; Popova E; Bader M; Svensson M; Espinosa A; Covacu R; Brundin L
Conference publication: 2024;:a17-a18
O15 B cell, T cell, cytotoxic/NK cell, and mitochondrial gene dysregulation patterns separate neuropsychiatric systemic lupus erythematosus patients into two distinct subgroups with differential anticipated response to targeted therapies
Lindblom J; Nikolopoulos D; Toro-Domínguez D; Carnero-Montoro E; Borghi MO; Castillo J; Iacobaeus E; Enman Y; Mohan C; Beretta L; Alarcón-Riquelme ME; Barturen G; Parodis I
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2024;30(3):451-452
Epidemiology of myelitis in Stockholm County 2008-2018; incidence, clinical characteristics, causes, and long-term outcomes
Jonsson DI; Sveinsson OA; Moeini N; Brundin L; Iacobaeus E
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2024;30(3):920
Brain atrophy and demyelination in MOGAD, AQP4+NMOSD and seronegative NMOSD
Hagbohm C; Ouellette R; Jonsson DI; Iacobaeus E; Granberg T
Preprint: PREPRINTS.ORG. 2023
Relapses and Serious Infections In Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab: A Swedish Cohort Study
Carlsson O; Jonsson DI; Brundin L; Iacobaeus E
Review: CELLULAR & MOLECULAR IMMUNOLOGY. 2023;20(6):613-625
Current perspectives on mesenchymal stromal cell therapy for graft versus host disease
Kadri N; Amu S; Iacobaeus E; Boberg E; Le Blanc K
Conference publication: BONE MARROW TRANSPLANTATION. 2023;58(SUPP1):37
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF MULTIPLE SCLEROSIS IN SWEDEN: AN OBSERVATIONAL COHORT STUDY
Silfverberg T; Zjukovskaja C; Iacobaeus E; Ljungman P; Einarsdottir S; Carlson K; Burman J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:622-623
Frequency of severe infections and correlation with immune markers in patients with neuromyelitis optica spectrum disorders treated with rituximab: a Swedish cohort study
Carlsson O; Jonsson DI; Brundin L; Iacobaeus E
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:850-851
Enlarged perivascular spaces are larger and more frequent in MOG plus NMOSD
Jonsson DI; Ouellette R; Coello RD; Ineichen B; Hagbohm C; Wardlaw J; Valdes-Hernandez M; Brundin L; Iacobaeus E; Granberg T
Conference publication: 2022;:a29.1-a2a29
PO.1.12 Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3aR as drug targets in neuropsychiatric systemic lupus erythematosus
Lindblom J; Toro-Domínguez D; Carnero-Montoro E; Borghi M; Castillo J; Iacobaeus E; Enman Y; Repsilber D; Mohan C; Alarcón-Riquelme M; Barturen G; Parodis I
Review: MULTIPLE SCLEROSIS JOURNAL. 2022;28(9):1424-1456
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Tur C; Dubessy A-L; Otero-Romero S; Amato MP; Derfuss T; Di Pauli F; Iacobaeus E; Mycko M; Abboud H; Achiron A; Bellinvia A; Boyko A; Casanova J-L; Clifford D; Dobson R; Farez MF; Filippi M; Fitzgerald KC; Fonderico M; Gouider R; Hacohen Y; Hellwig K; Hemmer B; Kappos L; Ladeira F; Lebrun-Frenay C; Louapre C; Magyari M; Mehling M; Oreja-Guevara C; Pandit L; Papeix C; Piehl F; Portaccio E; Ruiz-Camps I; Selmaj K; Simpson-Yap S; Siva A; Sorensen PS; Sormani MP; Trojano M; Vaknin-Dembinsky A; Vukusic S; Weinshenker B; Wiendl H; Winkelmann A; Rodas MIZ; Tintore M; Stankoff B
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:326
TRANSCRIPTOME PROFILING AND AUTOIMMUNITY-RELATED SEROLOGICAL MARKERS IDENTIFY TP53 AND C3AR AS DRUG TARGETS IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS
Lindblom J; Toro-Dominguez D; Borghi MO; Iacobaeus E; Enman Y; Repsilber D; Mohan C; Alarcon-Riquelme M; Barturen G; Parodis I
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):126-127
Neurological follow up and management of disease reactivation following aHSCT
Iacobaeus E
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2022;74:4417-4418
Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus
Lindblom J; Toro-Dominguez D; Carnero-Montoro E; Orietta Borghi M; Castillo J; Iacobaeus E; Enman Y; Mohan C; Alarcon-Riquelme M; Barturen G; Parodis I
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):326
Autologous hematopoietic stem cell transplantation in relapsing remitting multiple sclerosis patients:. single centre experience
Mavromati S; Brundin L; Iacobaeus E
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):169-170
Clinical characteristics and disability progression in late-onset MS
Mouresan EF; Mentesidou E; Berglund A; Hillert J; Mckay KA; Iacobaeus E
Review: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2022;15:17562864211066751
Smouldering multiple sclerosis: the 'real MS'.
Giovannoni G; Popescu V; Wuerfel J; Hellwig K; Iacobaeus E; Jensen MB; García-Domínguez JM; Sousa L; De Rossi N; Hupperts R; Fenu G; Bodini B; Kuusisto H-M; Stankoff B; Lycke J; Airas L; Granziera C; Scalfari A
Review: ACTA NEUROLOGICA SCANDINAVICA. 2021;144(3):229-235
Multiple sclerosis and COVID-19: The Swedish experience
Landtblom A-M; Berntsson SG; Bostrom I; Iacobaeus E
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):356
Comprehensive phenotypic and functional analyses of peripheral blood monocytes during MS disease progression
Iacobaeus E; Kadri N; Gavin C; Le Blanc K
Review: MULTIPLE SCLEROSIS JOURNAL. 2020;26(9):1352458520925369-1044
Aggressive multiple sclerosis (1): Towards a definition of the phenotype
Iacobaeus E; Arrambide G; Amato MP; Derfuss T; Vukusic S; Hemmer B; Tintore M; Brundin L
Review: MULTIPLE SCLEROSIS JOURNAL. 2020;26(9):1352458520924595-1063
Aggressive multiple sclerosis (2): Treatment
Arrambide G; Iacobaeus E; Amato MP; Derfuss T; Vukusic S; Hemmer B; Brundin L; Tintore M
Letter: HAEMATOLOGICA. 2020;105(6):e310-e314
Mental fatigue after allogeneic hematopoietic stem cell transplantation is associated with cognitive dysfunction, but not central nervous system inflammation
Boberg E; Kadri N; Winterling J; Davies LC; Bjorklund A; Msghina M; Iacobaeus E; Le Blanc K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):137-138
Clinical characteristics and outcome of late onset multiple sclerosis
Iacobaeus E; Berglund A; Mckay K; Brundin L; Hillert J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:533-534
Immunological and clinical follow up after autologous bone-marrow mesenchymal stromal cell therapy in progressive multiple sclerosis: a phase I clinical study
Iacobaeus E; Kadri N; Lefsihane K; Boberg E; Gavin C; Lilja A; Brundin L; Le Blanc K
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):285
Thymic function predicts response to mesenchymal stromal cell treatment in chronic GVHD
Boberg E; von Bahr L; Heldring N; Afram G; Iacobaeus E; Modin C; Garming-Legert K; Ljungman P; Sugars R; Davies L; Kadri N; Le Blanc K
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):335
Functional shift of myeloid-derived suppressor cells during Multiple Sclerosis disease course
Iacobaeus E; Douagi I; Jitschin R; Andren AT; Gavin C; Lefsihane K; Davies L; Olsson T; Mougiakakos D; Kadri N; Le Blanc K
Conference publication: BLOOD. 2017;130
Thymic Function Predicts Response to Mesenchymal Stromal Cell Treatment in Chronic GvHD: A Phase II Clinical Study
Boberg E; Von Bahr L; Heldring N; Afram G; Iacobaeus E; Lindstrom C; Garming-Legert K; Ljungman P; Sugars R; Davies L; Kadri N; Le Blanc K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:944
The national incidence of PML in Sweden, 1988-2013
Iacobaeus E
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2016;25:496-497
Pharmacological Treatments Preceding Diagnosis Of Progressive Multifocal Leukencephalopathy
Burkill S; Iacobaeus E; Bahmanyar S; Brundin L; Fored M; Olsson T; Montgomery S
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2016;25:99
Comorbid Diseases Preceding Diagnosis of Progressive Multifocal Leukencephalopathy
Iacobaeus E; Burkill S; Bahmanyar S; Brundin L; Fored M; Olsson T; Montgomery S
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:155
Immunohistochemical characterization of mesenchymal perivascular stem/stromal cells in multiple sclerosis and healthy brain tissue
Iacobaeus E; Sugars RV; Tornqvist AA; Alm JJ; Alkass K; Druid H; Roytta M; Le Blanc K
Letter: JOURNAL OF RHEUMATOLOGY. 2012;39(6):1299-1303
Progressive Multifocal Leukoencephalopathy in a Patient with Polymyositis: Case Report and Literature Review
Dastmalchi M; Laki J; Lundberg IE; Iacobaeus E
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2011;17:S119
Altered monocyte phenotype with decreased vascular endothelial growth factor-A in progressive multiple sclerosis
Iacobaeus E; Tham E; Khademi M; Olsson T; Piehl F
Thesis / dissertation: 2010
Establishment and applications of a multiple sclerosis biobank : analysis of biomarkers and therapeutic complications in MS
Iacobaeus, Ellen
Show more

Employments

Affiliated to Research, Department of Clinical Neuroscience, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, Karolinska Institutet, 2021
Degree Of Doctor Of Philosophy, Department of Clinical Neuroscience, Karolinska Institutet, 2010
University Medical Degree, Karolinska Institutet, 2001

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI